(redirected from Sumatriptan succinate)
Also found in: Medical.


A triptan drug, C14H21N3O2S, used also in the form of its succinate to treat migraine headache and cluster headache.

[suma-, origin unknown + -triptan, triptan suffix; see triptan.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n sumatriptán m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The company said ZEMBRACE SymTouch (sumatriptan succinate) injection, a drug-device combination product, is intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.
The active drug in SUD-001 is GlaxoSmithKline's sumatriptan succinate (Imitrex) which is available in injection, tablet or nasal spray form.
Sumatriptan: Net sales of sumatriptan succinate were $19.9 million in the fourth quarter compared to $18.3 million in the prior quarter.
The tablets - whose scientific name is Sumatriptan Succinate - will be sold in 25mg, 50mg, and 100mg amounts to begin shipping immediately, Mylan said in a press release today just ahead of the stock market's regular trading close.
(Chennai, India) was cleared to sell sumatriptan succinate tablets, used to treat migraine.
lmitrex Injection (sumatriptan succinate injection) is used for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes.
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
Spectrum's Abbreviated New Application (ANDA) for sumatriptan succinate injection alleges that the Orange Book listed patent is invalid, unenforceable and/or would not be infringed by Spectrum's product.
The Food and Drug Administration has approved a new injectable drug, sumatriptan succinate, for the acute treatment of migraine attacks.
Pharmaceutical company Dr Reddy's Laboratories (BSE:500124)(NSE:DRREDDY)(NYSE:RDY) revealed on Thursday the receipt of the US Food and Drug Administration (FDA) approval for ZEMBRACE SymTouch (sumatriptan succinate) injection for the treatment of acute migraine episodes.